|
Analyzing the Impact of Aging on the Immune System in the Context of COVID-19 Vaccination
|
*Center for iPS Cell Research and Application／Early Clinical Development
|
Clinical Research
|
Active, not recruiting
|
|
Investigation of Colorectal Cancer-Related Genes Using Peripheral Blood in Healthy Volunteers
|
*Early Clinical Development／Clinical Oncology
|
Clinical Research
|
Active, not recruiting
|
|
A Clinical Study for Treatment of Articular Cartilage Damage in Knee Joints With Allogeneic Induced Pluripotent Stem (iPS) Cell-derived Cartilage (TACK- iPS）
|
*Orthopaedic Surgery
|
Regenerative Medicine, Clinical Research
|
Active, not recruiting
|
|
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors
|
*Early Clinical Development／Clinical Oncology／Gastroenterology and Hepatology／Respiratory Medicine
|
Ⅰ
|
Enrolling by invitation
| <
| An Open-Label, Dose Escalation, Phase 1, First-in Human Study of TAK-102 in Adult Patients with GPC3-Expressing Previously Treated Solid Tumors
|
*Early Clinical Development／Hepatobiliary Pancreatic Surgery and Transplantation／Gastroentelogy and Hepatology
|
Ⅰ
|
Enrolling by invitation
|
|
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
|
*Early Clinical Development／Breast Surgery
|
Ⅰ
|
Enrolling by invitation
|
|
Study of DSP-0390 in Patients With Recurrent High-grade Glioma
|
*Neurosurgery
|
Ⅰ
|
Enrolling by invitation
|
| An open-label pharmacokinetic study of TS-142 in patients with hepatic impairment
|
*Early Clinical Development
|
Ⅰ
|
Enrolling by invitation
|
| A Phase 1 Study of Lomustine and PCV in Japanese Patients with Glioma (LOMG)
|
*Neurosurgery
|
Ⅰ
|
Enrolling by invitation
|
| Phase I/II trial for safety and pharmacokinetics of ENDOPIN in healthy and patients with postoperative pain
|
*Early Clinical Development／Thoracic Surgery
|
Ⅰ-Ⅱ
|
Enrolling by invitation
|
| Multicenter Phase II Investigator-Initiated Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic Therapy for Esophageal and Gastric Cancer
|
*Clinical Oncology
|
Ⅰ-Ⅱ
|
Enrolling by invitation
|
|
Nivolumab and Chemoradiotherapy for Esophageal Cancer
|
*Clinical Oncology
|
Ⅰ-Ⅱ
|
Active, not recruiting
|
|
Study of Sacituzumab Govitecan in Japanese Patients with Advanced Solid Tumors or Triple-negative Breast Cancer
|
*Breast Surgery
|
Ⅰ-Ⅱ
|
Enrolling by invitation
|
| Autologous Dendritic Cell Vaccine Therapy Targeting HTLV-1 Specific Antigen for Adult T-Cell Leukemia/Lymphoma (Phase II Study of Autologous DC Vaccine for ATLL)
|
*Department of Hematology and Oncology
|
Ⅱ
|
Enrolling by invitation
|
|
Phase II investigator-initiated trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer (Perfume trial)
|
*Clinical Oncology
|
Ⅱ
|
Enrolling by invitation
|
| A phase II basket study of necitumumab for EGFR amplification positive metastatic solid tumor (WJOG15021M)
|
*Clinical Oncology
|
Ⅱ
|
Enrolling by invitation
|
|
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPC
|
*Department of Radiation Oncolology and Image-Applied Therapy／Diagnostic Imaging and Nuclear Medicine／Department of Urology／Early Clinical Development
|
Ⅱ
|
Enrolling by invitation
|
|
Clinical Trial of Alectinib in Patients with ALK-Positive Rare Cancer (TACKLE)
|
*Clinical Oncology
|
Ⅱ
|
Enrolling by invitation
|
|
Multicenter Investigator-Initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
|
*Clinical Oncology
|
Ⅱ
|
Enrolling by invitation
|
|
A Randomized, Double-Blind, Cross-Over Study of S-600918 in Patients With Sleep Apnea Syndrome
|
*Respiratory Medicine
|
Ⅱ
|
Completed
|
| A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Ka Inhibitor in Patients with Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma
|
*Obstetrics and Gynecology
|
Ⅱ
|
Enrolling by invitation
|
| An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary central nervous system lymphoma (CRYSTAL trial)
|
*Department of Hematology and Oncology
|
Ⅱ
|
Enrolling by invitation
|
| A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors
|
*Urology
|
Ⅱ
|
Enrolling by invitation
|
| The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome (Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome)
|
*Nephrology
|
Ⅲ
|
Enrolling by invitation
|
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)
|
*Early Clinical Development/Clinical Oncology/Gastroenterology and Hepatology
|
Ⅲ
|
Enrolling by invitation
|
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician’s Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
|
*Breast Surgery
|
Ⅲ
|
Enrolling by invitation
|
| A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-101)
|
*Clinical Oncology
|
Ⅲ
|
Enrolling by invitation
|
|
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple-Negative Breast Cancer (IMpassion030)
|
*Breast Surgery
|
Ⅲ
|
Enrolling by invitation
|
|
A Phase III, Double Blind, Randomized Study of Bevacizumab in Combination With Carboplatin or Cisplatin + Etoposide + Atezolizumab Compared With Carboplatin or Cisplatin + Etoposide + Atezolizumab in Patients With Untreated ES-SCLC
|
*Respiratory Medicine
|
Ⅲ
|
Enrolling by invitation
|
|
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (GO41854, SKYSCRAPER-03)
|
*Respiratory Medicine
|
Ⅲ
|
Enrolling by invitation
|
|
DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Genomic Alterations (DS1062-A-U301, TROPION-Lung01)
|
*Respiratory Medicine
|
Ⅲ
|
Enrolling by invitation
|
|
Randomized Phase III Study of S-1 Based Chemotherapy Plus Nivolumab Versus S-1 Based Chemotherapy Alone for Patients With Locally Advanced/Borderline Resectable Pancreatic Cancer (Investigator Initiated Trial) (PENETRATE, JCOG1908E)
|
*Clinical Oncology
|
Ⅲ
|
Enrolling by invitation
|
|
A Phase III, Randomized, Double-blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab As Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
|
*Hepatobiliary Pancreatic Surgery and Transplantation
|
Ⅲ
|
Active, not recruiting
|
|
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy (ICC) in Participants with Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated with One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
|
*Breast Surgery
|
Ⅲ
|
Enrolling by invitation
|
|
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation
|
*Neurosurgery
|
Ⅲ
|
Enrolling by invitation
|
|
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
|
*Department of Radiation Oncolology and Image-Applied Therapy／Diagnostic Imaging and Nuclear Medicine／Department of Urology／Early Clinical Development
|
Ⅲ
|
Enrolling by invitation
|
|
Lenvatinib + pembrolizumab + chemotherapy compared to pembrolizumab + chemotherapy for the first-line treatment of metastatic esophageal cancer
|
*Clinical Oncology
|
Ⅲ
|
Enrolling by invitation
|
|
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
|
*Breast Surgery
|
Ⅲ
|
Enrolling by invitation
|
|
A Bioequivalence Study of an Anti-Cancer Drug in Healthy Volunteers
|
*Early Clinical Development／Clinical Oncology
|
–
|
Completed
|
|
A Bioequivalence Study of a Central Nervous System Acting Drug in Healthy Volunteers
|
*Clinical Oncology／Early Clinical Development
|
–
|
Completed
|
